Benjamin Dehay

Summary

Country: France

Publications

  1. doi Lysosomal impairment in Parkinson's disease
    Benjamin Dehay
    Institute of Neurodegenerative Diseases, University of Bordeaux Segalen, Centre National de Recherche Scientifique Unité Mixte de Recherche 5293, Bordeaux, France
    Mov Disord 28:725-32. 2013
  2. pmc Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove
    Benjamin Dehay
    Institut des Maladies Neurodégénératives, Universite de Bordeaux, CNRS UMR 5293, Bordeaux, France
    Autophagy 8:1389-91. 2012
  3. pmc Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
    Benjamin Dehay
    Insitute of Neurodegenerative Diseases, University of Bordeaux Segalen, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, 33076 Bordeaux, France
    Proc Natl Acad Sci U S A 109:9611-6. 2012
  4. ncbi New animal models of Parkinson's disease
    Benjamin Dehay
    Université Victor Segalen Bordeaux II, Centre National de la Recherche Scientifique, Institute of Neurodegenerative Diseases, Bordeaux, France
    Mov Disord 26:1198-1205. 2011
  5. doi Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia
    Michel Engeln
    University de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France
    Biol Psychiatry 79:354-61. 2016
  6. pmc Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate
    Marie Hélène Canron
    Univ de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F 33000 Bordeaux, France
    Sci Rep 2:910. 2012
  7. pmc Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques
    Benjamin Dehay
    Univ de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F 33000 Bordeaux, France
    Sci Rep 2:253. 2012
  8. doi Alpha-synuclein propagation: New insights from animal models
    Benjamin Dehay
    Universite de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
    Mov Disord 31:161-8. 2016
  9. doi Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
    Benjamin Dehay
    Institute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unite Mixte de Recherche, Bordeaux, France
    Lancet Neurol 14:855-66. 2015
  10. doi Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression
    Mathieu Bourdenx
    University de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France
    Acta Neuropathol Commun 3:46. 2015

Collaborators

Detail Information

Publications12

  1. doi Lysosomal impairment in Parkinson's disease
    Benjamin Dehay
    Institute of Neurodegenerative Diseases, University of Bordeaux Segalen, Centre National de Recherche Scientifique Unité Mixte de Recherche 5293, Bordeaux, France
    Mov Disord 28:725-32. 2013
    ....
  2. pmc Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove
    Benjamin Dehay
    Institut des Maladies Neurodégénératives, Universite de Bordeaux, CNRS UMR 5293, Bordeaux, France
    Autophagy 8:1389-91. 2012
    ..Our results unravel an instrumental role of ATP13A2 in lysosomal function and in cell viability. Altogether, our results validate ATP13A2 as a likely therapeutic target against PD degeneration...
  3. pmc Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration
    Benjamin Dehay
    Insitute of Neurodegenerative Diseases, University of Bordeaux Segalen, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, 33076 Bordeaux, France
    Proc Natl Acad Sci U S A 109:9611-6. 2012
    ..Our results unravel an instrumental role of ATP13A2 deficiency on lysosomal function and cell viability and demonstrate the feasibility and therapeutic potential of modulating ATP13A2 levels in the context of PD...
  4. ncbi New animal models of Parkinson's disease
    Benjamin Dehay
    Université Victor Segalen Bordeaux II, Centre National de la Recherche Scientifique, Institute of Neurodegenerative Diseases, Bordeaux, France
    Mov Disord 26:1198-1205. 2011
    ....
  5. doi Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia
    Michel Engeln
    University de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France National Centre for Scientific Research, Institut des Maladies Neurodégénératives, Bordeaux, France
    Biol Psychiatry 79:354-61. 2016
    ..However, the relationship between the electrical activity of FosB/ΔFosB-expressing neurons and LID manifestation is unknown...
  6. pmc Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate
    Marie Hélène Canron
    Univ de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F 33000 Bordeaux, France
    Sci Rep 2:910. 2012
    ..Microcebus murinus may provide a model to study age-associated α-synucleinopathy and for testing putative therapeutic interventions for both Alzheimer's and Parkinson's diseases...
  7. pmc Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques
    Benjamin Dehay
    Univ de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F 33000 Bordeaux, France
    Sci Rep 2:253. 2012
    ..The present data pave the way to large-scale genetic modelling of brain diseases in the rhesus macaque...
  8. doi Alpha-synuclein propagation: New insights from animal models
    Benjamin Dehay
    Universite de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France
    Mov Disord 31:161-8. 2016
    ..Finally, we discuss the current underlying molecular and cellular mechanisms and future therapeutic strategies targeting alpha-synuclein propagation. © 2015 International Parkinson and Movement Disorder Society. ..
  9. doi Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
    Benjamin Dehay
    Institute of Neurodegenerative Diseases, University of Bordeaux, Centre National de la Recherche Scientifique Unite Mixte de Recherche, Bordeaux, France
    Lancet Neurol 14:855-66. 2015
    ..We critically assess the potential of experimental therapies targeting α-synuclein, and discuss steps that need to be taken for target validation and drug development. ..
  10. doi Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression
    Mathieu Bourdenx
    University de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, 33000, Bordeaux, France
    Acta Neuropathol Commun 3:46. 2015
    ....
  11. doi Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies
    Pierre Olivier Fernagut
    Univ de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F 33000 Bordeaux, France CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F 33000 Bordeaux, France
    Neurobiol Dis 67:133-9. 2014
    ..In this personal view, we will review evidence, and discuss why MSA could prove the most relevant clinical model for assessing treatments that target mechanisms operating in all synucleinopathies...
  12. pmc PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking
    Gregory Porras
    Universite de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France
    J Clin Invest 122:3977-89. 2012
    ..These findings indicate that altering D1R trafficking via synapse-associated scaffolding proteins may be useful in the treatment of dyskinesia in Parkinson's patients...